We're honored to be selected as a 2025 #ComcastRISE recipient! In addition to a $5,000 monetary grant, we also receive #SmallBusiness consultation, access to educational tools, technology and equipment services, and media support, including a 180-day TV commercial campaign.

#TechnologyMakeover

In a landscape where every day counts, the ROI on high-quality #MedicalWriting is real and measurable. Read our LinkedIn post for info about building trust with regulators, stakeholders, and patients: www.linkedin.com/company/synt...

#RegulatoryAffairs #DrugDevelopment #ClinicalDevelopment

Compliance is non-negotiable in this industry. But with the right integration strategy and the right partners, AI becomes a force multiplier. Read our post on LinkedIn for more insights: www.linkedin.com/company/synt...

#RegulatoryWriting #Compliance #ClinicalDevelopment #QualityAssurance

In rare diseases, the “n of 1” matters, and efficacy narratives help tell that story with clarity and impact. For more on #EfficacyNarratives in #RareDiseases, read our latest LinkedIn post: www.linkedin.com/feed/update/...

#ClinicalDevelopment #RegulatoryStrategy #OrphanDrugs

When people think about #RegulatoryWriting, they often focus on the what: protocols, CSRs, CTD modules. But the real value comes from the how and the outcomes it enables.

Whatever obstacles your team is facing, we are here to help: www.synterex.com/services/pro...

#MedicalWriting #LifeSciences

AI tools are evolving at breakneck speed, but how far can they take us in crafting better, faster manuscripts?

Here's a look at where we're headed: www.synterex.com/post/dear-ai...

#AIinHealthcare #GenAI #EthicalAI #ClinicalResearch

In regulatory affairs, compliance is only as strong as your integration across teams and systems.

For more effective focus on your people and processes, collaborate with our experts at Synterex. Learn more: www.synterex.com/services/reg...

#RegulatoryAffairs SynterexSolutions

At Synterex, we work with teams to preempt common challenges in #ClinicalDocumentation projects by:

🟢 Establishing structured, realistic review schedules
🟢 Aligning data availability with document timelines
🟢 Building in flexibility without compromising quality

#MedicalWriting #LifeSciences

Unsure how to navigate GDPR or the EU AI Act in your clinical trials? There's a webinar for that! Join us and AVS Life Sciences in two weeks for "Smarter Tools, Stricter Rules." Register now: us02web.zoom.us/meeting/regi...

#GDPR #EUAIAct #ClinicalTrials

Bringing new #VeterinaryProducts to the market is just as complex as with a human medicine, sometimes even more so. At Synterex, our #RegulatoryAffairs consulting team has the experience and expertise to get you there.

Learn more: www.synterex.com/services/vet....

Pharma analyst George El-Helou recently told Clinical Trials Arena that, despite industry innovation, #Regulatory guidelines "still tend to be reactive rather than proactive."

Get ahead of the regulatory curve with #AgileWriter now: www.synterex.com/software-sol....

Regulatory submissions and health authority interactions seem to only get more and more complex.

Read our new blog post to learn about #AgileWriter and AI in #StructuredContent management: www.synterex.com/post/structu....

Psychological priming is a phenomenon where exposure to one stimulus influences the response to another.

How does it apply to #ClinicalDocumentation? Learn more: www.synterex.com/post/psychol...

If you've visited our website in the last few weeks, then you were one of the first to see our new look. Our new website improves user experience, increases accessibility, and shares more about us in order to better serve our clients.

Head to www.synterex.com to let us know what you think!

We've been selected as a 2025 Fierce DEI Awards winner for Leadership in Health Equity by #FierceHealthcare! Thanks to all the team members, partners, and clients who helped get us here.

Learn more: www.fiercehealthcare.com/book/fierce-...

#FierceHealthcare #FierceDEIAwards #HealthEquity #DEI

To move AI from novelty to a strategic asset in #MedicalWriting, the industry needs to not only adopt the tools but rethink its processes, responsibilities, and value.

Our President, Jeanette Towles, contributed to an #AMWA paper on this topic: amwajournal.org/index.php/am....

The FD&C Act requires all new drugs to undergo an intensive review process by the FDA. However, there are gaps in the guidance/regulations for drug investigations involving children of varying ages.

Download our #whitepaper on DIA marketplace for more info: marketplace.diaglobal.org/listing/synt...